NYSE:ABBV - AbbVie Stock Price, Forecast & News

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie declared a -- dividend on Friday, November 1st. Stockholders of record on Wednesday, January 15th will be paid a dividend of $1.18 per share on Friday, February 14th. This represents a dividend yield of 5.93%. The ex-dividend date of this dividend is Tuesday, January 14th. This is a positive change from AbbVie's previous -- dividend of $1.07. View AbbVie's Dividend History.

AbbVie announced that its Board of Directors has authorized a share repurchase program on Thursday, December 13th 2018, which allows the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy up to 3.8% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's leadership believes its shares are undervalued.

AbbVie Inc (NYSE:ABBV) announced its quarterly earnings data on Friday, November, 1st. The company reported $2.33 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.29 by $0.04. The company had revenue of $8.48 billion for the quarter, compared to analyst estimates of $8.37 billion. AbbVie had a negative return on equity of 155.96% and a net margin of 9.90%. The firm's revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period last year, the business earned $2.14 earnings per share. View AbbVie's Earnings History.

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for AbbVie.

AbbVie will be holding an earnings conference call on Friday, February 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

AbbVie issued an update on its FY19 earnings guidance on Friday, November, 1st. The company provided EPS guidance of $8.90-8.92 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.90.

13 Wall Street analysts have issued 12-month target prices for AbbVie's stock. Their forecasts range from $66.61 to $98.00. On average, they anticipate AbbVie's share price to reach $86.33 in the next twelve months. This suggests a possible upside of 2.5% from the stock's current price. View Analyst Price Targets for AbbVie.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

Press coverage about ABBV stock has been trending somewhat negative recently, InfoTrie reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. AbbVie earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for AbbVie.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Valeant Pharmaceuticals Intl (VRX) and AT&T (T).

AbbVie's stock is owned by many different of institutional and retail investors. Top institutional shareholders include New York State Teachers Retirement System (0.15%), Artemis Investment Management LLP (0.07%), Hamlin Capital Management LLC (0.06%), Strs Ohio (0.06%), State of Michigan Retirement System (0.06%) and Candriam Luxembourg S.C.A. (0.05%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Galibier Capital Management Ltd., Ambassador Advisors LLC, Candriam Luxembourg S.C.A., Commerzbank Aktiengesellschaft FI, Meag Munich Ergo Kapitalanlagegesellschaft MBH, OLD National Bancorp IN, Strs Ohio and Usca Ria LLC. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Laura J Schumacher and Timothy J Richmond. View Insider Buying and Selling for AbbVie.

ABBV stock was bought by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Raub Brock Capital Management LP, Zurcher Kantonalbank Zurich Cantonalbank, Artemis Investment Management LLP, CHURCHILL MANAGEMENT Corp, State of Michigan Retirement System, 6 Meridian and First American Bank. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $84.23.

AbbVie has a market capitalization of $124.56 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.

The official website for AbbVie is http://www.abbvie.com/.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.